DYN
NASDAQDyne Therapeutics Inc.
Price$23.73+0.86 (+3.76%)
01:30 PM07:45 PM
News · 26 weeks136+35%
2026-01-182026-07-12
Mix10590d
- SEC Filings59(56%)
- Insider32(30%)
- Other12(11%)
- Leadership1(1%)
- Analyst1(1%)
Latest news
25 items- INSIDERDirector Rhodes Jason P sold $17,858,492 worth of shares (777,451 units at $22.97) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERDirector Rhodes Jason P sold $10,712,550 worth of shares (504,695 units at $21.23) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERChief Financial Officer Lucera Erick sold $48,114 worth of shares (2,362 units at $20.37), decreasing direct ownership by 2% to 121,563 units (SEC Form 4) to satisfy tax liability4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- ANALYSTTD Cowen initiated coverage on Dyne TherapeuticsTD Cowen initiated coverage of Dyne Therapeutics with a rating of Buy
- INSIDERDirector Rhodes Jason P sold $5,646,497 worth of shares (267,760 units at $21.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERDirector Kersten Dirk sold $5,464,611 worth of shares (263,962 units at $20.70) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERSEC Form 4 filed by Director Greene Barry E4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 3 filed by new insider Greene Barry E3 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- PRDyne Therapeutics Appoints Barry Greene to Board of DirectorsWALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of biopharmaceutical industry experience and a track record of building and scaling innovative companies from development through commercialization across rare diseases, neuroscience, and oncology. "Dyne is approaching a planned transformation into a commercial biotechnology company. In anticipation of potential product launches and revenue generation, w
DYN FAQ
7 questionsWhat does Dyne Therapeutics Inc. do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.Where does DYN stock trade?
Dyne Therapeutics Inc. (DYN) is listed on NASDAQ.What sector and industry is DYN in?
Dyne Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dyne Therapeutics Inc. go public?
Dyne Therapeutics Inc. (DYN) completed its IPO in 2020.What are analysts saying about DYN?
Dyne Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-06-26. Recent price targets range from $1300.00 to $4600.00.What companies are similar to DYN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DYN side-by-side with any of them on Quantisnow.How can I track DYN on Quantisnow?
Quantisnow aggregates Dyne Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYN to receive live email and push alerts on every new disclosure.